Novo Nordisk has been looking to diversify its lineup in recent years, and is developing medicines in other fields. The ...
Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...
Bernstein analysts led by Florent Cespedes increased their price target on Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO) stock to DKK620.00, up from DKK600.00, while maintaining a Market Perform rating.
Morgan Stanley (NYSE:MS) initiated coverage on shares of Novo Nordisk (NOVOB:DC) (NYSE: NYSE:NVO), a global healthcare company specializing in diabetes care and other serious chronic conditions. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results